Latest Schedule 13G passive stakes

Redmile Group, LLC and Jeremy C. Green have reported a beneficial ownership stake of 3.6% in Scholar Rock Holding Corporation, holding 4,311,092 shares.

Elliott Investment Management L.P. has reported beneficial ownership of 5.8% of Pinterest, Inc.'s Class A Common Stock as of June 30, 2026.

Encompass Capital entities and Todd J. Kantor report a combined 7.60% and 6.04% stake in EagleRock Land, LLC Class A shares as of June 30, 2026.

Select Equity Group, L.P. and George S. Loening have jointly reported beneficial ownership of 2,436,873 common shares, representing 6.2% of Signet Jewelers Ltd.

Discovery Capital Management, LLC, Robert K. Citrone, and Discovery Global Opportunity Master Fund, Ltd. have filed an amendment to their Schedule 13G, reporting changes in their beneficial ownership of AMC Entertainment Holdings, Inc. Class A common stock.

Soros Fund Management LLC and George Soros have filed a Schedule 13G amendment, appointing attorneys-in-fact for executing regulatory filings related to securities ownership.

Leon G. Cooperman, through Capital L.P., has reported beneficial ownership of 3,261,216 shares, representing 12.4% of WhiteHawk Minerals Corp.'s Class A Common Stock.

Newtyn Management, LLC has filed a Schedule 13G amendment indicating it is an exit filing, reducing its beneficial ownership of Enviri Corp common stock to 1.3%.

Several Biotechnology Value Funds have updated their beneficial ownership filings for Nektar Therapeutics, reporting a combined stake of 7.1% as of June 30, 2026.

TCG Crossover Fund II, L.P., along with affiliated entities and individual Chen Yu, has increased its beneficial ownership in Tango Therapeutics, Inc. to 7.0%, acquiring 10,147,867 shares.

Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen have jointly filed to report beneficial ownership of 5.0% of Neuronetics, Inc. common stock.

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed a Schedule 13G, reporting beneficial ownership of 7.5% of Future Money Acquisition Corporation's ordinary shares as of June 30, 2026.

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed a Schedule 13G, reporting beneficial ownership of 7.5% of Future Money Acquisition Corporation's ordinary shares as of June 30, 2026.

Vestal Point Capital, LP, along with its Chief Investment Officer Ryan Wilder, has reported beneficial ownership of 5.4% of Monte Rosa Therapeutics, Inc. common stock.

Point72 Asset Management, L.P., along with related entities and Steven A. Cohen, has reported beneficial ownership of 1.4% of Sutro Biopharma, Inc.'s common stock as of June 30, 2026.

Southeastern Asset Management and Longleaf Partners Small-Cap Fund jointly report beneficial ownership of 5.4% of GCI Liberty's Series C GCI Group Common Stock as of June 30, 2026.

Southeastern Asset Management, Inc. and Longleaf Partners Small-Cap Fund report a combined 5.1% stake in Empire State Realty Trust, Inc. Class A Common Stock.

Southeastern Asset Management, Inc. has filed a Schedule 13G, reporting beneficial ownership of 4.6% of People Inc.'s common stock as of June 30, 2026.

Karpus Management, Inc. has updated its beneficial ownership filing for Oxford Lane Capital Corp.'s preferred stock, reporting a 6.08% stake.

Lind Global Fund III LP, Lind Global Partners III LLC, and Jeff Easton have filed a Schedule 13G detailing their beneficial ownership of Iveda Solutions, Inc. common stock, limited by warrant conversion restrictions.

Van Eck Associates Corporation has filed a Schedule 13G, reporting beneficial ownership of 9.7% of Denison Mines Corp. common stock.

Commodore Capital LP and its affiliates have reported a beneficial ownership of 1.8% of Definium Therapeutics, Inc. common shares, acquiring them through a combination of direct holdings and pre-funded warrants.

Vivo Opportunity Fund Holdings, L.P. and its affiliates have disclosed beneficial ownership of 9.99% of SAB Biotherapeutics, Inc. common stock, including convertible securities and warrants.

Lynwood Capital Management Inc., Ben Shapiro, and Lynwood Opportunities Master Fund have reported beneficial ownership of 5.0% of Rein Therapeutics, Inc. common stock as of June 30, 2026.

Van Eck Associates Corporation has reported a beneficial ownership of 6.5% in Coeur Mining, Inc., holding 67,029,794 shares.

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed a Schedule 13G, reporting beneficial ownership of 6.7% of Breeze Acquisition Corp II's ordinary shares as of June 30, 2026.

Point72 Asset Management, L.P. and related entities have reported beneficial ownership of 3.8% of Design Therapeutics, Inc. common stock as of June 30, 2026.

Jericho Capital Asset Management L.P. and Josh Resnick have reported beneficial ownership of 7.2% of Core Scientific, Inc.'s common stock as of June 30, 2026.

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed a Schedule 13G, reporting beneficial ownership of 6.7% of Breeze Acquisition Corp II's ordinary shares as of June 30, 2026.

Vestal Point Capital, LP, through its managed funds, has disclosed beneficial ownership of 8,050,000 shares, representing 7.8% of Nurix Therapeutics, Inc. common stock.